Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study was to investigate the acute and chronic effect of whole-body vibration exercise on serum insulin-like growth factor-1 levels in women with fibromyalgia (FM). It was hypothesized that women with FM would exhibit an increase in IGF-1 following both acute and chronic WBV. Twenty-four women with FM were randomized into two groups: Vibration Group (VG) and Control Group (CG). The VG underwent a protocol with WBV exercise twice a week for a total of six weeks, whereas the CG performed the same protocol without vibratory stimulus. Both groups continued with their usual pharmacological treatment. Serum IGF-1 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA). To test the effect of chronic WBV, serum IGF-1 measurements were taken at baseline and at weeks 1,3, and 6 of intervention. To test the effect of acute WBV, within week 1, serum IGF-1 measurements were taken before and immediately following a session of WBV.

Condition or disease	Intervention/treatment	Phase
Fibromyalgia; Hormonal Responses to Exercise in Patients With Fibromyalgia.	Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands; Device: Placebo Whole-body vibration exercise	Not Applicable

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	24 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Participant)
Primary Purpose:	Treatment
Official Title:	Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia
Study Start Date :	December 2004
Actual Primary Completion Date :	January 2005
Actual Study Completion Date :	January 2005

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: VG; Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.	Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands; Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
Placebo Comparator: CG; The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.	Device: Placebo Whole-body vibration exercise; Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Serum IGF-1 levels [ Time Frame: Baseline, Week 1, Week 3, Week 6 ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	35 Years to 69 Years (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria for at least three years.

Exclusion Criteria:

• Orthopedic limitation, or cardiovascular, pulmonary, or metabolic disease that would preclude exercise.
• Participation in any other study.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Spain
Institut Nacional d'Educación Física de Catalunya
Barcelona, Spain, 08038

Sponsors and Collaborators

Institut Nacional d'Educacio Fisica de Catalunya

Investigators

Principal Investigator:	Eduard Alentorn-Geli, MD	INEFC

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Eduard Alentorn-Geli, MD, INEFC
ClinicalTrials.gov Identifier:	NCT00650715 History of Changes
Other Study ID Numbers:	WBVIGF1FM
First Posted:	April 2, 2008
Last Update Posted:	April 2, 2008
Last Verified:	March 2008

Keywords provided by Institut Nacional d'Educacio Fisica de Catalunya:

Fibromyalgia; Whole-Body vibration; Exercise; IGF-1

Additional relevant MeSH terms:

Fibromyalgia; Myofascial Pain Syndromes; Muscular Diseases; Musculoskeletal Diseases	Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases